# Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease

> **NCT01387178** · — · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 22223 (actual)

## Conditions studied

- Pulmonary Disease, Chronic Obstructive

## Interventions

- **DRUG:** fluticasone propionate/salmeterol 250µg/50µg (FSC)
- **DRUG:** tiotropium bromide (TIO)

## Key facts

- **NCT ID:** NCT01387178
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-02
- **Final completion:** 2010-02
- **Target enrollment:** 22223 (ACTUAL)
- **Last updated:** 2017-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01387178

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01387178, "Outcomes From Initial Maintenance Therapy With Fluticasone Propionate 250/Salmeterol 50 (FSC) or Tiotropium in Chronic Obstructive Pulmonary Disease". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT01387178. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*